Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 5/20 | 0.36 |
| ▸ | NPY1R | P25929 | 4/20 | 0.36 |
| ▸ | NPY2R | P49146 | 3/20 | 0.36 |
| ▸ | CCKBR | P32239 | 7/20 | 0.36 |
| ▸ | IL1RN | P18510 | 2/20 | 0.36 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.36 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.36 |
| ▸ | CCKAR | P32238 | 1/20 | 0.35 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.35 |
| ▸ | AMY2A | P04746 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27428810 | 1.00 | NPY4R (0.36) | NPY4RNPY1RNPY2RCCKBRIL1RN | |
| SCHEMBL27428984 | 0.93 | CCKBR (0.40) | CCKBRCCKAR | |
| SCHEMBL27434126 | 0.93 | CCKBR (0.40) | CCKBRCCKAR | |
| SCHEMBL27428871 | 0.87 | CCKBR (0.37) | CCKBRCCKARAMY2A | |
| SCHEMBL27429224 | 0.86 | PAX8 (0.41) | CCKBRAMY2A | |
| SCHEMBL27429130 | 0.85 | KISS1R (0.34) | CCKBRKISS1RAMY2A | |
| SCHEMBL27428911 | 0.83 | CCKBR (0.38) | CCKBRCCKARKISS1R | |
| SCHEMBL27434029 | 0.81 | CCKBR (0.40) | CCKBRCCKARAMY2A | |
| SCHEMBL27429128 | 0.79 | CCKBR (0.34) | CCKBRCCKARAMY2A | |
| SCHEMBL27428842 | 0.78 | IL1RN (0.37) | CCKBRIL1RNERAP2ERAP1CCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | VIP, QPCT, PTMS | NPY4R 433/4885NPY1R 680/4885NPY2R 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.